LOS ANGELES , Aug. 14, 2024 /PRNewswire/ -- ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, today announced the appointment of Ian Somaiya to its board of directors.
Mr. Somaiya, currently chief financial officer (CFO) of NewAmsterdam Pharma Company N.V.
, brings more than 25 years of financial and operational leadership, including more than two decades on Wall Street as a prominent biotechnology research analyst. "Ian is an experienced executive with a deep understanding of the industry landscape and expertise in corporate strategy, financial planning and fundraising," said Sumant Ramachandra, M.D.
, Ph.D., chief executive officer of ImmPACT Bio.
"We are pleased to welcome him to our board of directors where his guidance will be important as we continue to scale the company." Mr. Somaiya added, "ImmPACT Bio has the potential to make a transformative difference in the treatment of multiple cancers and autoimmune diseases with their innovative bispecific CAR T-cell therapies.
I look forward to joining ImmPACT Bio's board and partnering with the team as they further advance their clinical programs with several anticipated data readouts." Mr. Somaiya has held executive leadership positions, including CFO and chief business officer of Elucida Oncology, where he led fundraising and corporate strategy and, before that, as CFO of TCR .